stonedinvestor said: Bank of America- UP! This can go a number of ways from here. Way A) Market sniffs a soft landing and gets a soft CPI which sets off a massive rally. Which the Fed answers with .75 and market tanks. Way B) Market rallies next week into CPI print which shockingly shows persistent high inflation still. Stocks crash. Fed answers with .50 <---------- Saves The Market.- Thanks for finding this! It's B obviously-! are you not watching current events. The question of whether we get .50 is certainly up to debate. I am the only one who has suggested that vs 300 trained economists. So I wouldn't hang my hat on that part. But I do think tomorrow's numbers (CPI) will be a lot better.////
S&P 500 (^GSPC)- Ok so watch our Lizard Level... If we hold and rebound that will be a triple bottom. SNP - SNP Real Time Price. 4,020.68-89.73 (-2.18%) As of 09:41AM EDT.
S&P 500 (^GSPC) Lizard Level** SNP - SNP Real Time Price. 3,919.84-35.16(-0.89%)<------------------------
Li-Cycle Holdings Corp. (LICY)- looks Good. NYSE - Nasdaq Real Time Price. 7.12-0.30 (-4.04%) As of 09:46AM EDT.
Guys I'm totally F*ed it's back To The Gym day after two months off or more.... I will probably be hurting bad later... Did anyone watch Cramer last night? He made a complete ass of himself. He took on the Bear thesis one by one explained everything away and went long long long. (gulp)
I suspect we can get cute here and find the trade. But 3% short term yields in bonds are going to start looking pretty good to down 20% investors....
GBA UPGRADE TO BUY Fluence Energy, Inc. (FLNC)-- NasdaqGS - NasdaqGS Real Time Price. 18.13-0.79 (-4.18%) As of 11:49AM EDT.
Mirati Therapeutics, Inc. (MRTX)-- This is a bit controversial we took this one up so it's always dangerous to revisit at a higher level. I think it's a buy again. 82.11-4.49 (-5.18%) As of 11:50AM EDT.
shares of clinical-stage biotech Mirati Therapeutics (NASDAQ:MRTX) added ~11% in the pre-market trading Wednesday after Amgen (AMGN) announced a lung cancer medication that rivals the company’s key asset adagrasib reached the primary objective in a late-stage trial. AMGN’s Lumakras is a KRAS G12C inhibitor similar to MRTX’s adagrasib, which is currently undergoing the U.S. regulatory review for non-small cell lung cancer (NSCLC) as a second-line option. That was yesterday MRTX was trading at this price of $83 and spiked yesterday...so no pull in. The AMGN drug is great but doesn't extend anyone's life... However it does target the same receptor as MRTX... so the hope is MRTX can actually show increased life (decrease in mortality rate)